Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 8c; Cash and Cash Equivalents of $240.3M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
November 4, 2021 7:00 AM EDTOn-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease
Losmapimod update planned for Q1 2022
Raised $144.2 million in gross proceeds from August 2021 public offering, extending cash runway into 2024
Conference call scheduled for 8:00 a.m. ET today
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business... More
